

FOREUM Platinum Recognition awarded for first time

13 June, 2018, Kilchberg, Switzerland – The FOREUM Foundation for Research in Rheumatology has for the first time awarded platinum recognition. Recognition has been awarded to Eli Lilly and Pfizer. The winners today receive the platinum recognition during the opening plenary session of the EULAR Annual Congress in Amsterdam, Netherlands.

FOREUM Foundation for Research in Rheumatology is devoted to promote research in rheumatic and musculoskeletal diseases (RMDs) as an independent research funding body in rheumatology research. To achieve this goal, FOREUM seeks to raise funds from various donors; through donations, basic and applied research of the highest quality can be supported to reduce the burden of disease for people with RMDs.

Gerd Burmester, FOREUM President Board of Trustees, states of the platinum recognition, “FOREUM is very grateful for Eli Lilly and Pfizer’s support and ongoing commitment for research in rheumatology at the platinum donor level”.

Receiving the recognition, Dr. Inmaculada de La Torre, International Therapy Area Medical Leader Rheumatology at Eli Lilly said, “Eli Lilly recognises the need for the highest levels of commitment to enabling research in the field of rheumatology, and it is with great pride and honour that the company receives this recognition today.”

Representative of Pfizer, Dr. Isabelle Logeart, Regional Medical Team Lead Inflammation & Immunology, IDM, commented, “Pfizer is committed to advancing research and transforming the lives of patients with inflammatory conditions. To be one of the first to receive the FOREUM Platinum Recognition is an honor – and highly appreciated”.

FOREUM Foundation for Research in Rheumatology seeks to raise funds from interested commercial and non-commercial donors that share FOREUM’s vision and goals: Recognising that research and

innovation in this field are crucial for improving both the prevention and the management of RMDs and, hence, the living, working and socio-economic conditions of more than 120 million people in Europe afflicted with a rheumatic or musculoskeletal disease.

FOREUM Foundation for Research in Rheumatology is directed and supervised by an international Board of Trustees comprising renowned researchers and scientific experts in rheumatology. An international Executive Committee defines the strategic agenda for FOREUM, coordinates operational aspects and evaluates and decides on funding of peer-reviewed research proposals. The committee also includes a patient representative.

An international scientific committee of experts from relevant fields of rheumatology acts as an advisory body for all scientific and methodological aspects. The committee includes patient and health professional representatives. The organisational structure thereby ensures that FOREUM fulfils a need in rheumatology research and acts according to the highest standards and ethics of scientific research.

About FOREUM

FOREUM Foundation for Research in Rheumatology is promoting health in individuals with rheumatic and musculoskeletal diseases through effective research. FOREUM is an independent fundraising institution for research funding based in Switzerland. FOREUM is recognized by the Swiss authorities according to Swiss law and foundation regulations as a not-for-profit organisation. FOREUM is supported by EULAR, the European League Against Rheumatism.

Contact

Florian Klett, General Secretary, florian.klett@foreum.org, Tel. +41 43 311 55 66.